Identification of cathepsin K in the peritoneal metastasis of ovarian carcinoma using in-silico, gene expression analysis

Journal of Cancer

Volumn 7, Issue 6, 2016, Pages 722-729

  Xu, Haiming ^a   Ma, Yu ^b   Zhang, Yan ^b   Pan, Zimin ^b   Lu, Yan ^b   Liu, Pengyuan ^b   Lu, Bingjian ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CTSK (cathepsin K); Metastasis; Microarray; Ovarian carcinoma

Indexed keywords

CA 125 ANTIGEN; CATHEPSIN K; CELL PROTEIN; COLLAGENASE 3; FIBROBLAST GROWTH FACTOR 1; GREMLIN 1; HUMAN EPIDIDYMIS SPECIFIC PROTEIN 4; UNCLASSIFIED DRUG;

ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPID METABOLISM; MICROARRAY ANALYSIS; MICROFLUIDIC ANALYSIS; OVARY CARCINOMA; PERITONEUM METASTASIS; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; YOUDEN INDEX;

EID: 84976496991     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.14277     Document Type: Article

References (26)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
2. Mok SC, Chao J, Skates S, et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst. 2001;93:1458-64.
3. Bonome T, Levine DA, Shih J, et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008;68:5478-86.
4. Sabatier R, Finetti P, Bonensea J, et al. A seven-gene prognostic model for platinum-treated ovarian carcinomas. Br J Cancer. 2011;105:304-11.
5. Ouellet V, Guyot MC, Le Page C, et al. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer. 2006;119:599-607.
6. Selvanayagam ZE, Cheung TH, Wei N, et al. Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. Cancer Genet Cytogenet. 2004;154:63-6.
7. Gómez-Raposo C, Mendiola M, Barriuso J, et al. Molecular characterization of ovarian cancer by gene-expression profiling. Gynecol Oncol. 2010;118:88-92.
8. Fekete T, Rásó E, Pete I, et al. Meta-analysis of gene expression profiles associated with histological classification and survival in 829 ovarian cancer samples. Int J Cancer. 2012;131:95-105.
9. Bignotti E, Tassi RA, Calza S, et al. Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. Am J Obstet Gynecol. 2007;196:245.e1-11.
10. Lancaster JM, Dressman HK, Clarke JP, et al. Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer. 2006;16:1733-45.
11. Györffy B, Dietel M, Fekete T, et al. A snapshot of microarray-generated gene expression signatures associated with ovarian carcinoma. Int J Gynecol Cancer. 2008;18:1215-33.
12. Zhang L, Wei L, Shen G, et al. Cathepsin L is involved in proliferation and invasion of ovarian cancer cells. Mol Med Rep. 2015;11:468-74.
13. Zhang W, Yang HC, Wang Q, et al. Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis. Anticancer Res. 2011;31:3423-8.
14. Lösch A, Schindl M, Kohlberger P, et al. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density. Gynecol Oncol. 2004;92:545-52.
15. Tang HY, Beer LA, Chang-Wong T, et al. A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer. J Proteome Res. 2012;11:678-91.
16. Kleer CG, Bloushtain-Qimron N, Chen YH, et al: Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clin Cancer Res. 2008;14:5357-67.
17. Duong LT, Wesolowski GA, Leung P, et al. Efficacy of a Cathepsin K Inhibitor in a Preclinical Model for Prevention and Treatment of Breast Cancer Bone Metastasis. Mol Cancer Ther. 2014;13:2898-909.
18. Zheng G, Martignoni G, Antonescu C, et al. A broad survey of cathepsin K immunoreactivity in human neoplasms. Am J Clin Pathol. 2013;139:151-9.
19. Zhao G, Chen J, Deng Y, et al. Identification of NDRG1-regulated genes associated with invasive potential in cervical and ovarian cancer cells. Biochem Biophys Res Commun. 2011;408:154-9.
20. Karlsen MA, Sandhu N, Høgdall C, et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2012;127:379-3.
21. Karlsen NS, Karlsen MA, Høgdall CK, et al. HE4 Tissue Expression and Serum HE4 Levels in Healthy Individuals and Patients with Benign or Malignant Tumors: A Systematic Review. Cancer Epidemiol Biomarkers Prev. 2014;23:2285-95.
22. Nieman KM, Kenny HA, Penicka CV, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17:1498-503.
23. Stetler-Stevenson WG. The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2. Cancer Metastasis Rev. 2008;27:57-66.
24. Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer. 2004;11:709-24.
25. Smith G, Ng MT, Shepherd L, et al. Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer. Br J Cancer. 2012;107:1327-36.
26. Karagiannis GS, Musrap N, Saraon P, et al. Bone morphogenetic protein antagonist gremlin-1 regulates colon cancer progression. Biol Chem. 2015;396:163-83.